Janssen and Bayer to present Xarelto data at ACC.16

Janssen and Bayer will be attending the American College of Cardiology's forthcoming Annual Scientific Session (ACC.16) to share their latest Xarelto research findings.

The companies will give a total of 14 data presentations at the conference in Chicago in early April, including real-world findings confirming the safety of Xarelto in a high-risk group of patients with non-valvular atrial fibrillation and concomitant diabetes.

This research complements previous Xarelto clinical trials by providing important insights to physicians on how the medicine is performing among those seen in everyday practice, with data drawn from 91,000 patients in real-world settings.

Other topic areas that will be presented include adherence, hospitalisation length of stay and hospital costs, including outcomes in those undergoing treatment for venous thromboembolism.

Dr Paul Burton, vice-president of medical affairs at Janssen, said: "It is critically important that we continue to assess the performance of once-daily Xarelto in high-risk non-valvular atrial fibrillation patients seen in everyday practice."

The European Medicines Agency last month confirmed the positive risk-benefit profile of Xarelto in stroke prevention among patients with atrial fibrillation.